Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

VABYSMO 120 MG/ML SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/VABYSMO 120 MG/ML SOLUCION INYECTABLE

Approved

STANDARD

VABYSMO 120 MG/ML SOLUCION INYECTABLE

Roche Registration Gmbh🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Sep 29, 2022
Approval ID: 765fc58b3c05ed9b
Company: Roche Registration Gmbh
Type: Standard

Approval Details

Approval Id: 765fc58b3c05ed9b
Drug Cima Aemps Name: VABYSMO 120 MG/ML SOLUCION INYECTABLE
Register Number: 1221683001
Holder Company Name: Roche Registration Gmbh
Marketing Company Name: Roche Farma S.A.
Holder Company Detail Path: /organization/roche-registration-gmbh
Authorization Date: 2022-09-29
Dosage Form: SOLUCIÓN INYECTABLE
Dose: 120 MG/ML
Route Of Administration: VÍA INTRAVÍTREA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Roche Registration Gmbh
Company Detail Path: /organization/roche-registration-gmbh

Company Information

Pharmaceutical Company Name: Roche Registration GmbH
Country Name: Germany
City Name: grenzach-wyhlen,baden-württemberg,country_de
Address: Emil-Barell-Str. 1

Active Ingredients

FARICIMAB

28,8 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Sep 29, 2022

Approval ID

765fc58b3c05ed9b

Type

Standard

Back to CIMA-AEMPS Approvals